Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Results of a Phase II Study of PD-1 Inhibition in Advanced Myeloproliferative Neoplasms

Gabriela S. Hobbs, MD, Cansu Cimen Bozkus, Martha Wadleigh, MD, Lonette Sandy, Mikaela Doughtery, Kathryn Johnson, Gillian Sanchez, Julia E. Foster, NP, Molly Macrae, Tina T. Som, RN, Michal Bar-Natan, MD, Richard M. Stone, MD, Erin Moshier, MS, Camelia Iancu-Rubin, PhD, John Mascarenhas, MD

Blood (2020) 136 (Supplement 1): 14–15.

https://doi.org/10.1182/blood-2020-137294

Published: 2020

Journal Articles

Prognostic Significance of Hospitalization Status at Second Cycle of Hypomethylating Agent Induction Therapy in Acute Myeloid Leukemia Patients Ineligible for Intensive Chemotherapy

Douglas Tremblay, MD, Rafael Madero-Marroquin, MD, Guido Lancman, MD, Alexander Coltoff, MD, Jonathan Feld, MD, Jessica Caro, MD, Nicole Zubizarreta, MPH, Marina Kremyanskaya, Alla Keyzner, MD, Michal Bar-Natan, MD, Shyamala C. Navada, MD, Lewis R. Silverman, Janice L. Gabrilove, MD, John Mascarenhas, MD

Blood (2019) 134 (Supplement_1): 5102.

https://doi.org/10.1182/blood-2019-123288

Published: 2019

Journal Articles

Significance of Abnormalities of PPM1D in Myeloproliferative Neoplasms

Bridget Marcellino, MD PhD, Joseph Tripodi, Michal Bar-Natan, MD, Harry Fruchtman, Noushin Farnoud, PhD, Min Lu, PhD, Heidi E. Kosiorek, MS, Amylou C. Dueck, PhD, Raajit K. Rampal, MD PhD, John Mascarenhas, MD, Vesna Najfeld, PhD, Ronald Hoffman, MD

Blood (2019) 134 (Supplement_1): 4207.

https://doi.org/10.1182/blood-2019-129565

Published: 2019

Journal Articles

MUC1 Inhibition Overcomes Chemotherapy Resistance in Acute Myeloid Leukemia

Myrna Rita Nahas, MD, Dina Stroopinsky, PhD, Hasan Rajabi, PhD, Ashujit Tagde, PhD, Athalia Rachel Pyzer, MD, Salvia Jain, MD, Maxwell Douglas Coll, Michal Bar-Natan, MD, Rebecca Karp, MD, Katarina Luptakova, MD, Kristen Anna Palmer, Poorvi Somaiya, Jon Arnason, MD, Malgorzata McMasters, MD, Robin Joyce, MD, James D. Levine, MD, Donald Kufe, MD, David Avigan, MD, Jacalyn Rosenblatt

Blood (2015) 126 (23): 2473.

https://doi.org/10.1182/blood.V126.23.2473.2473

Published: 2015

Journal Articles

Immunomodulatory Effect of MUC1-C in Acute Myeloid Leukemia

Blood (2015) 126 (23): 3659.

https://doi.org/10.1182/blood.V126.23.3659.3659

Published: 2015

Journal Articles

MUC-1 Regulates MiR34a Expression in Acute Myeloid Leukemia Cells Resulting in an Accumulation of Granulocytic Myeloid-Derived Suppressor Cells

Blood (2015) 126 (23): 643.

https://doi.org/10.1182/blood.V126.23.643.643

Published: 2015

Journal Articles

Mucin-1 (MUC1) Oncoprotein in Multiple Myeloma Cells Inhibits the Th1 Responses By Down Regulating the Expression of Mir-200c and up-Regulating the PDL1 Expression

Hasan Rajabi, PhD, Maxwell Douglas Coll, Jacalyn Rosenblatt, MD, Li Yin, PhD, Dina Stroopinsky, PhD, Katarina Luptakova, MD, Baldev Vasir, PhD, Athalia Rachel Pyzer, MD, Kristen Palmer, Michal Bar-Natan, MD, Salvia Jain, MD, Poorvi Somaiya, MSc, Jon Arnason, MD, Donald Kufe, MD, David Avigan, MD

Blood (2014) 124 (21): 2072.

https://doi.org/10.1182/blood.V124.21.2072.2072

Published: 2014

Journal Articles

Continuous Platelet Transfusion Increases Platelet Increment in Refractory Hemato-Oncological Patients – a Single Center Experience

Sharon Tzadok, MD, Anna Gurevich, B MDSc, Aida Inbal, MD, Michal Bar-Natan, MD, Ofir Wolach, MD, Pia Raanani, MD

Blood (2014) 124 (21): 2888.

https://doi.org/10.1182/blood.V124.21.2888.2888

Published: 2014

Journal Articles

Bone Marrow Stroma Protects Myeloma Cells from Cytotoxic Damage Via Induction of the Oncoprotein MUC1

Michal Bar-Natan, MD, Katarina Luptakova, MD, Maxwell Douglas Coll, Dina Stroopinsky, PhD, Hasan Rajabi, PhD, Athalia Rachel Pyzer, MD, Kristen A Palmer, Michaela R. Reagan, PhD, Poorvi Somaiya, MSc, Salvia Jain, MD, Jon Arnason, MD, Irene M. Ghobrial, MD, Jacalyn Rosenblatt, MD, Kenneth C. Anderson, MD, Donald Kufe, MD, David Avigan, MD

Blood (2014) 124 (21): 3378.

https://doi.org/10.1182/blood.V124.21.3378.3378

Published: 2014

Journal Articles

MUC1 As a Potential Therapeutic Target in Cutaneous T-Cell Lymphoma

Salvia Jain, MD, Maroof Alam, PhD, Hasan Rajabi, PhD, Dina Stroopinsky, PhD, Li Yin, PhD, Jacalyn Rosenblatt, MD, Kristen A Palmer, Maxwell Douglas Coll, Athalia Rachel Pyzer, MD, Katarina Luptakova, MD, Jon Arnason, MD, Robin Joyce, MD, Michal Bar-Natan, MD, Poorvi Somaiya, MSc, Rachael A Clark, MDPhD, Thomas S. Kupper, MD, Donald Kufe, MD, David Avigan, MD

Blood (2014) 124 (21): 808.

https://doi.org/10.1182/blood.V124.21.808.808

Published: 2014

Journal Articles

Myeloid-Derived Suppressor Cells Are Expanded in Patients with AML and Are Dependent on MUC1 Expression

Athalia Rachel Pyzer, MD, Dina Stroopinsky, PhD, Jacalyn Rosenblatt, MD, Kristen Anna Palmer, BA, Maxwell Douglas Coll, Michal Bar-Natan, MD, Hasan Rajabi, PhD, Poorvi Somaiya, MSc, Katarina Luptakova, MD, Salvia Jain, MD, Malgorzata McMasters, MD, James D. Levine, MD, Jon Arnason, MD, Donald Kufe, MD, David Avigan, MD

Blood (2014) 124 (21): 226.

https://doi.org/10.1182/blood.V124.21.226.226

Published: 2014

Journal Articles

Immunomodulatory Effect of SGI-110, a Novel Hypomethylating Agent in Acute Myeloid Leukemia (AML)

Dina Stroopinsky, PhD, Athalia Rachel Pyzer, MD, Kristen A Palmer, Maxwell D Coll, Michal Bar-Natan, MD, Hasan Rajabi, PhD, Poorvi Somaiya, MSc, Katarina Luptakova, MD, Salvia Jain, MD, Malgorzata McMasters, MD, James D. Levine, MD, Jon Arnason, MD, Pietro Taverna, PhD, Donald Kufe, MD, David Avigan, MD, Jacalyn Rosenblatt, MD

Blood (2014) 124 (21): 2303.

https://doi.org/10.1182/blood.V124.21.2303.2303

Published: 2014

Journal Articles

Comparison between Two Reduced-Intensity Conditioning Regimens Prior to Allogeneic Stem Cell Transplantation: Fludarabine and Melphalan Is Associated with Higher Incidence of Acute Graft-Versus-Host Disease and Non-Relapse Mortality and Lower Incidence of Relapse Than Fludarabine and Busulfan.

Avichai Shimoni, MD, Izhar Hardan, MD, Noga Shem-Tov, MD, Ronit Yerushalmi, MD, Michal Bar-Natan, MD, Friderikos Tsolakis, MD, Arnon Nagler, MD

Blood (2006) 108 (11): 2947.

https://doi.org/10.1182/blood.V108.11.2947.2947

Published: 2006

NARROW

Results of a Phase II Study of PD-1 Inhibition in Advanced Myeloproliferative Neoplasms

Prognostic Significance of Hospitalization Status at Second Cycle of Hypomethylating Agent Induction Therapy in Acute Myeloid Leukemia Patients Ineligible for Intensive Chemotherapy

Significance of Abnormalities of PPM1D in Myeloproliferative Neoplasms

MUC1 Inhibition Overcomes Chemotherapy Resistance in Acute Myeloid Leukemia

Immunomodulatory Effect of MUC1-C in Acute Myeloid Leukemia

MUC-1 Regulates MiR34a Expression in Acute Myeloid Leukemia Cells Resulting in an Accumulation of Granulocytic Myeloid-Derived Suppressor Cells

Mucin-1 (MUC1) Oncoprotein in Multiple Myeloma Cells Inhibits the Th1 Responses By Down Regulating the Expression of Mir-200c and up-Regulating the PDL1 Expression

Continuous Platelet Transfusion Increases Platelet Increment in Refractory Hemato-Oncological Patients – a Single Center Experience

Bone Marrow Stroma Protects Myeloma Cells from Cytotoxic Damage Via Induction of the Oncoprotein MUC1

MUC1 As a Potential Therapeutic Target in Cutaneous T-Cell Lymphoma

Myeloid-Derived Suppressor Cells Are Expanded in Patients with AML and Are Dependent on MUC1 Expression

Immunomodulatory Effect of SGI-110, a Novel Hypomethylating Agent in Acute Myeloid Leukemia (AML)

Comparison between Two Reduced-Intensity Conditioning Regimens Prior to Allogeneic Stem Cell Transplantation: Fludarabine and Melphalan Is Associated with Higher Incidence of Acute Graft-Versus-Host Disease and Non-Relapse Mortality and Lower Incidence of Relapse Than Fludarabine and Busulfan.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only